Effects of estrogen and selective estrogen receptor modulators on hemostasis and inflammation: Potential differences among drugs

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 175-180

  Cushman, Mary ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Hormone replacement therapy (HRT); Inflammation; Menopause; Myocardial infarction; Risk factors; Selective estrogen receptor modulators (SERMs); Thrombosis; Women

Indexed keywords

ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; FEMALE; HEART INFARCTION; HEMOSTASIS; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0035680438     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04017.x     Document Type: Conference Paper

References (33)

1. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
3. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
4. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
5. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial
6. Hormone replacement therapy, inflammation, and hemostasis in elderly women
7. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
8. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
9. The effects of raloxifene compared with hormone replacement therapy on homocysteine and C-reactive protein in healthy postmenopausal women: A randomized controlled trial
10. Tamoxifen and cardiac risk factor in healthy women: Suggestion of an anti-inflammatory effect
11. A prospective study of C-reactive protein and risk of future cardiovascular events among apparently healthy women
12. Hormone replacement therapy and sensitive C-reactive protein concentration in women with type-2 diabetes
13. Effects of raloxifene and hormone replacement therapy on markers of inflammation in healthy postmenopausal women
14. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
15. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation
16. Direct proinflammatory effect of C-reactive protein on human endothelial cells
17. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis
18. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
19. Effect of tamoxifen on measurements of hemostasis in healthy women
20. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
21. Coagulation activation following estrogen administration to postmenopausal women
22. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study
23. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
24. Fibrinolytic activation markers predict myocardial infarction in the elderly: The Cardiovascular Health Study
25. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
26. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis
27. Role of clotting factor VIII in effect of yon Willebrand factor on occurrence of deep-vein thrombosis
28. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study
29. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the Cardiovascular Health Study
30. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: Relationships to hormone replacement therapy
31. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (the Leiden Thrombophilia Study)
32. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk
33. "Normal" thrombin generation